Early bactericidal activity of isoniazid in pulmonary tuberculosis: Optimization of methodology

Richard Hafner, Johathan A. Cohn, David J. Wright, Nancy E. Dunlap, Merrill J. Egorin, Mary E. Enama, Katherine Muth, Charles A. Peloquin, Natan Mor, Leonid B. Heifets, Penny Phillips, Rafael E Campo, Portia James, Michael Sension, Michelle Bourie, Mallory Witt, Sally Kruger, David Mushatt, Debra Greenspan

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Early bactericidal activity (EBA) of antituberculosis drugs is the rate of decrease in the concentration of tubercle bacilli sputum during the initial days of therapy. The study reported here was designed to optimize the methodology for obtaining precise EBA measurements. The study compared the results with two versus five treatment days; overnight sputum collections with early morning collections; and quantitative smears for acid-fast bacilli (AFB) with quantitative cultures. Isoniazid (INH) was used as a model drug. Among 28 smear-positive patients enrolled in the study in five cities in the United States, 16 were evaluable (INH-susceptible tuberculosis [TB] and adequate sputum collections). The mean baseline bacterial load was 6.69 log10 cfu/ml (SE = 0.24). Quantitative culture of 10- or 12-h sputum collections obtained on two baseline days and treatment Day 5 was the optimal method for EBA measurement. The mean 5-d EBA was 0.21 log10 cfu/ml/d (SE = 0.03; p < 0.001), and the EBA appeared to be constant during the first five treatment days. On the basis of these data, multiarm studies of investigational drugs will require 25 evaluable subjects per arm to detect (80% power and two-tailed alpha of 0.05) an EBA at least 50% as large as the EBA of INH. In countries with a low incidence of TB, the usefulness of this methodology for rapidly assessing new antituberculosis agents may be limited by the relatively large number of subjects required to compare EBA values across treatment arms.

Original languageEnglish
Pages (from-to)918-923
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume156
Issue number3 I
StatePublished - Oct 1 1997

Fingerprint

Isoniazid
Pulmonary Tuberculosis
Sputum
Bacillus
Tuberculosis
Investigational Drugs
Therapeutics
Bacterial Load
Pharmaceutical Preparations
Acids
Incidence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Hafner, R., Cohn, J. A., Wright, D. J., Dunlap, N. E., Egorin, M. J., Enama, M. E., ... Greenspan, D. (1997). Early bactericidal activity of isoniazid in pulmonary tuberculosis: Optimization of methodology. American Journal of Respiratory and Critical Care Medicine, 156(3 I), 918-923.

Early bactericidal activity of isoniazid in pulmonary tuberculosis : Optimization of methodology. / Hafner, Richard; Cohn, Johathan A.; Wright, David J.; Dunlap, Nancy E.; Egorin, Merrill J.; Enama, Mary E.; Muth, Katherine; Peloquin, Charles A.; Mor, Natan; Heifets, Leonid B.; Phillips, Penny; Campo, Rafael E; James, Portia; Sension, Michael; Bourie, Michelle; Witt, Mallory; Kruger, Sally; Mushatt, David; Greenspan, Debra.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 156, No. 3 I, 01.10.1997, p. 918-923.

Research output: Contribution to journalArticle

Hafner, R, Cohn, JA, Wright, DJ, Dunlap, NE, Egorin, MJ, Enama, ME, Muth, K, Peloquin, CA, Mor, N, Heifets, LB, Phillips, P, Campo, RE, James, P, Sension, M, Bourie, M, Witt, M, Kruger, S, Mushatt, D & Greenspan, D 1997, 'Early bactericidal activity of isoniazid in pulmonary tuberculosis: Optimization of methodology', American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 3 I, pp. 918-923.
Hafner, Richard ; Cohn, Johathan A. ; Wright, David J. ; Dunlap, Nancy E. ; Egorin, Merrill J. ; Enama, Mary E. ; Muth, Katherine ; Peloquin, Charles A. ; Mor, Natan ; Heifets, Leonid B. ; Phillips, Penny ; Campo, Rafael E ; James, Portia ; Sension, Michael ; Bourie, Michelle ; Witt, Mallory ; Kruger, Sally ; Mushatt, David ; Greenspan, Debra. / Early bactericidal activity of isoniazid in pulmonary tuberculosis : Optimization of methodology. In: American Journal of Respiratory and Critical Care Medicine. 1997 ; Vol. 156, No. 3 I. pp. 918-923.
@article{1c7c85a4699a4286962f525b98e80ec9,
title = "Early bactericidal activity of isoniazid in pulmonary tuberculosis: Optimization of methodology",
abstract = "Early bactericidal activity (EBA) of antituberculosis drugs is the rate of decrease in the concentration of tubercle bacilli sputum during the initial days of therapy. The study reported here was designed to optimize the methodology for obtaining precise EBA measurements. The study compared the results with two versus five treatment days; overnight sputum collections with early morning collections; and quantitative smears for acid-fast bacilli (AFB) with quantitative cultures. Isoniazid (INH) was used as a model drug. Among 28 smear-positive patients enrolled in the study in five cities in the United States, 16 were evaluable (INH-susceptible tuberculosis [TB] and adequate sputum collections). The mean baseline bacterial load was 6.69 log10 cfu/ml (SE = 0.24). Quantitative culture of 10- or 12-h sputum collections obtained on two baseline days and treatment Day 5 was the optimal method for EBA measurement. The mean 5-d EBA was 0.21 log10 cfu/ml/d (SE = 0.03; p < 0.001), and the EBA appeared to be constant during the first five treatment days. On the basis of these data, multiarm studies of investigational drugs will require 25 evaluable subjects per arm to detect (80{\%} power and two-tailed alpha of 0.05) an EBA at least 50{\%} as large as the EBA of INH. In countries with a low incidence of TB, the usefulness of this methodology for rapidly assessing new antituberculosis agents may be limited by the relatively large number of subjects required to compare EBA values across treatment arms.",
author = "Richard Hafner and Cohn, {Johathan A.} and Wright, {David J.} and Dunlap, {Nancy E.} and Egorin, {Merrill J.} and Enama, {Mary E.} and Katherine Muth and Peloquin, {Charles A.} and Natan Mor and Heifets, {Leonid B.} and Penny Phillips and Campo, {Rafael E} and Portia James and Michael Sension and Michelle Bourie and Mallory Witt and Sally Kruger and David Mushatt and Debra Greenspan",
year = "1997",
month = "10",
day = "1",
language = "English",
volume = "156",
pages = "918--923",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3 I",

}

TY - JOUR

T1 - Early bactericidal activity of isoniazid in pulmonary tuberculosis

T2 - Optimization of methodology

AU - Hafner, Richard

AU - Cohn, Johathan A.

AU - Wright, David J.

AU - Dunlap, Nancy E.

AU - Egorin, Merrill J.

AU - Enama, Mary E.

AU - Muth, Katherine

AU - Peloquin, Charles A.

AU - Mor, Natan

AU - Heifets, Leonid B.

AU - Phillips, Penny

AU - Campo, Rafael E

AU - James, Portia

AU - Sension, Michael

AU - Bourie, Michelle

AU - Witt, Mallory

AU - Kruger, Sally

AU - Mushatt, David

AU - Greenspan, Debra

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Early bactericidal activity (EBA) of antituberculosis drugs is the rate of decrease in the concentration of tubercle bacilli sputum during the initial days of therapy. The study reported here was designed to optimize the methodology for obtaining precise EBA measurements. The study compared the results with two versus five treatment days; overnight sputum collections with early morning collections; and quantitative smears for acid-fast bacilli (AFB) with quantitative cultures. Isoniazid (INH) was used as a model drug. Among 28 smear-positive patients enrolled in the study in five cities in the United States, 16 were evaluable (INH-susceptible tuberculosis [TB] and adequate sputum collections). The mean baseline bacterial load was 6.69 log10 cfu/ml (SE = 0.24). Quantitative culture of 10- or 12-h sputum collections obtained on two baseline days and treatment Day 5 was the optimal method for EBA measurement. The mean 5-d EBA was 0.21 log10 cfu/ml/d (SE = 0.03; p < 0.001), and the EBA appeared to be constant during the first five treatment days. On the basis of these data, multiarm studies of investigational drugs will require 25 evaluable subjects per arm to detect (80% power and two-tailed alpha of 0.05) an EBA at least 50% as large as the EBA of INH. In countries with a low incidence of TB, the usefulness of this methodology for rapidly assessing new antituberculosis agents may be limited by the relatively large number of subjects required to compare EBA values across treatment arms.

AB - Early bactericidal activity (EBA) of antituberculosis drugs is the rate of decrease in the concentration of tubercle bacilli sputum during the initial days of therapy. The study reported here was designed to optimize the methodology for obtaining precise EBA measurements. The study compared the results with two versus five treatment days; overnight sputum collections with early morning collections; and quantitative smears for acid-fast bacilli (AFB) with quantitative cultures. Isoniazid (INH) was used as a model drug. Among 28 smear-positive patients enrolled in the study in five cities in the United States, 16 were evaluable (INH-susceptible tuberculosis [TB] and adequate sputum collections). The mean baseline bacterial load was 6.69 log10 cfu/ml (SE = 0.24). Quantitative culture of 10- or 12-h sputum collections obtained on two baseline days and treatment Day 5 was the optimal method for EBA measurement. The mean 5-d EBA was 0.21 log10 cfu/ml/d (SE = 0.03; p < 0.001), and the EBA appeared to be constant during the first five treatment days. On the basis of these data, multiarm studies of investigational drugs will require 25 evaluable subjects per arm to detect (80% power and two-tailed alpha of 0.05) an EBA at least 50% as large as the EBA of INH. In countries with a low incidence of TB, the usefulness of this methodology for rapidly assessing new antituberculosis agents may be limited by the relatively large number of subjects required to compare EBA values across treatment arms.

UR - http://www.scopus.com/inward/record.url?scp=9844255045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844255045&partnerID=8YFLogxK

M3 - Article

C2 - 9310014

AN - SCOPUS:9844255045

VL - 156

SP - 918

EP - 923

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3 I

ER -